Abstract:Identifying improved treatments for severe and refractory coccidioidomycosis (Valley fever) is needed. This endemic fungal disease is common in North and South America, and cases have increased substantially over the last 30 years. The current standard of care, oral daily fluconazole, often fails to completely eradicate Coccidioides infection; however, the high cost of identifying new compounds effective in treating Valley fever is a barrier to improving treatment. Therefore, repurposing existing pharmaceutical agents in combination with fluconazole therapy is an attractive option. We screened the Library of Pharmacologically Active Compounds (LOPAC) small molecule library for compounds that inhibited fungal growth in vitro and determined IC50 values for a subset of compounds. Based on these findings, we tested a small subset of these agents to validate the screen, as well as to test the performance of fluconazole in a combination therapy approach, as compared with fluconazole alone, in a murine model. We observed that combination therapy of tamoxifen:fluconazole and sertraline:fluconazole significantly reduced the burden of live fungus in the lung compared with fluconazole alone, and we observed reduced or nonexistent dissemination. These results suggest that tamoxifen and sertraline may be repurposed as adjunctive agents in the treatment of this important fungal disease. Importance: Developing new drugs, especially for regional orphan diseases, such as Valley Fever, is a slow and costly endeavor. However, there is a wealth of FDA-approved drugs available for repurposing, offering a more economical and expedited approach to improve treatment. Those existing compounds with antifungal properties can become novel therapies with relative ease: a considerable advantage for patients in need of alternative treatment. Despite the scope of remaining tasks, our comprehensive screening of potential candidates has revealed promising combinations for further exploration. This effort outlines a practical pipeline for Valley fever drug screening and identifies viable drug combinations that could impact patients more rapidly than single drug development pathways.

Discovery and Repurposing of Pharmaceutical Agents as Antifungals: activity against

In vitro small molecule screening to inform novel candidates for use in fluconazole combination therapy in vivo against Coccidioides

Novel Potentially Antifungal Hybrids of 5-Flucytosine and Fluconazole: Design, Synthesis and Bioactive Evaluation.

Drug Repurposing of Haloperidol: Discovery of New Benzocyclane Derivatives As Potent Antifungal Agents Against Cryptococcosis and Candidiasis.

Discovery of Novel Sertraline Derivatives as Potent Anti- Cryptococcus Agents

Repurposing an Inhibitor of Ribosomal Biogenesis with Broad Anti-Fungal Activity

Discovery of Piperidol Derivatives for Combinational Treatment of Azole-Resistant Candidiasis

Design, Synthesis, and In Vitro and In Vivo Evaluation of Novel Fluconazole-Based Compounds with Promising Antifungal Activities

Synthesis and antifungal evaluation of novel triazole derivatives bearing a pyrazole-methoxyl moiety

Discovery of Novel Thiosemicarbazides Containing 1,3,5-Triazines Derivatives as Potential Synergists against Fluconazole-Resistant Candida albicans

Antifungal activity of the repurposed drug disulfiram against Cryptococcus neoformans

Discovery of Novel α,β-Unsaturated Amide Derivatives as Candidate Antifungals to Overcome Fungal Resistance

Drug repurposing strategies in the development of potential antifungal agents

Discovery of Novel Sertraline Derivatives as Potent Anti-CryptococcusAgents br

Design, Synthesis, Evaluation and Optimization of Novel Azole Analogues As Potent Antifungal Agents

Combination of fluconazole with natural compounds: A promising strategy to manage resistant Candida albicans infections

Discovery of Novel Tetrazoles Featuring a Pyrazole Moiety as Potent and Highly Selective Antifungal Agents

Synergistic Effect of the Combination of Deferoxamine and Fluconazole in Vitro and in Vivo Against Fluconazole-Resistant Candida Spp.

Deep-learning based repurposing of FDA-approved drugs against Candida albicans dihydrofolate reductase and molecular dynamics study

Strategies of Pharmacological Repositioning for the Treatment of Medically Relevant Mycoses

Discovery of Deguelin Derivatives in Combination with Fluconazole Against Drug-Resistant Candida Albicans